Engineered immune cells take on lupus in early trial
NCT ID NCT06038474
First seen Jan 04, 2026 · Last updated May 19, 2026 · Updated 17 times
Summary
This early study tests a new treatment called Descartes-08 for people with systemic lupus erythematosus (SLE), a chronic autoimmune disease. Six adults whose lupus remains active despite standard medications will receive these specially engineered immune cells. The main goals are to check safety and see if the therapy can reduce disease activity over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Profound Research LLC
Oceanside, California, 92056, United States
Conditions
Explore the condition pages connected to this study.